Imaging lung function using hyperpolarized 129Xe MRI
Official title: Hyperpolarized 129Xe MR Imaging of the Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
Run by Duke University · NCT01280994 · Data updated 2026-11-12
This study is testing a new MRI method using a special gas to see if it can better help people with interstitial lung disease understand how their lungs are working.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 445 (estimated) |
| Sponsor | Duke University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Durham, North Carolina) |
| Status | Recruiting |
| Started | January 2011 |
| Main results expected | December 2030 |
| Study ends | December 2030 |
| Registry record updated | January 16, 2026 |
| Trial ID | NCT01280994 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with pulmonary dysfunction or healthy controls without any pulmonary conditions.
✕Probably not a fit
Patients under 18 years old, those with contraindications for MRI, or those with acute respiratory illnesses may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the effectiveness of MRI with hyperpolarized 129Xe gas for assessing pulmonary function in patients with interstitial lung disease. The research focuses on three specific imaging techniques: visualizing 129Xe ventilation distribution, analyzing alveolar microstructure through the apparent diffusion coefficient, and observing the gas's dissolution in pulmonary blood and tissues. By providing a non-invasive method to assess lung function, this study seeks to improve sensitivity in detecting lung pathologies compared to traditional pulmonary function tests.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate and sensitive assessments of lung function, improving diagnosis and treatment for patients with chronic pulmonary diseases.
How similar studies have gone: While the use of hyperpolarized gas MRI is a relatively novel approach, similar imaging techniques have shown promise in other studies, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Inclusion Criteria for Healthy Control Subjects 1. Subject has no diagnosed pulmonary conditions 2. Subject has not smoked in the previous 5 years. 3. Smoking history, if any, is less than or equal to 5 pack-years. Inclusion Criteria for Subjects with lung disease 1. Subject has a diagnosis of pulmonary dysfunction made by a physician 2. No acute worsening of pulmonary function in the past 30 days Exclusion Criteria: 1. Subject is less than 18 years old 2. MRI is contraindicated based on responses to MRI screening questionaire 3. Subject is pregnant or lactating 4. Respiratory illness of a bacterial or viral etiology within 30 days of MRI 5. Subject has received an investigational medicinal product (not including 129Xe) within 30 days of MRI 6. Subject has any form of known cardiac arrhythmia 7. Subject does not fit into 129Xe vest coil used for MRI 8. Subject cannot hold his/her breath for 15 seconds 9. Subject deemed unlikely to be able to comply with instructions during imaging
Where it's running
-
Duke University Medical Center
Durham, North Carolina, United States Recruiting
Study contacts
- Principal investigator: Joseph Mammarappallil, M.D. — Duke University
- Study coordinator: Jennifer Korzekwinski
- Email: jennifer.korzekwinski@duke.edu
- Phone: 919-681-7362
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Telitacicept for primary Sjögren’s with interstitial lung disease
This study tests whether Telitacicept helps people with primary Sjögren’s syndrome and interstitial lung disease compared with standard immunosuppressants.
-
Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients
This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.
-
Treprostinil Palmitil Inhalation Powder for Progressive Pulmonary Fibrosis
A 52-week study will test whether once-daily Treprostinil Palmitil Inhalation Powder helps lung function in adults with progressive pulmonary fibrosis compared to placebo.
-
Treatment Response in Myositis-Associated RP-ILD in Adults
This study tests how people with myositis and rapidly progressing interstitial lung disease respond to an immunosuppressant treatment approach.
-
AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT
This study tests how well the AccuPulmo CT Portal can identify pulmonary fibrosis on existing chest CT scans from adults at Taichung Veterans General Hospital.
-
See if 18F-FAPI-74 PET/CT can better detect fibrosis in heart and lung disease
Researchers are testing a new PET/CT tracer, 18F-FAPI-74, to see if it can reveal early fibrotic changes in people with heart and lung diseases who are at risk for tissue scarring.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.